Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Chia seeds may boost fetal brain DHA during obesity-linked pregnancy

In obese pregnant rats, chia seed enrichment helped shift omega-3 metabolism, increasing DHA availability in maternal tissues, placenta, and fetal brain lipid profiles during a critical developmental window. Study: Chia seed enrichment in high-fat-high-sugar d

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

In obese pregnant rats, chia seed enrichment helped shift omega-3 metabolism, increasing DHA availability in maternal tissues, placenta, and fetal brain lipid profiles during a critical developmental window.

Study: Chia seed enrichment in high-fat-high-sugar diet-induced obesity: a strategy to increase DHA levels in maternal tissues and in fetal placenta and brain during pregnancy. Image Credit: Very Hungry Owl / Shutterstock

In a recent study published in the journal Prostaglandins, Leukotrienes and Essential Fatty Acids, a group of researchers examined whether adding chia seeds to a high-fat-high-sugar diet during pregnancy increases docosahexaenoic acid (DHA) availability in maternal tissues, the placenta, and the fetal brain in a rat model of diet-induced obesity.

Chia Seeds and Pregnancy DHA Background

Obesity during pregnancy has become a growing concern, with millions of women consuming Western-style diets rich in sugar and saturated fats but poor in healthy omega-3 fatty acids. This imbalance may disrupt fetal brain development and increase the likelihood of future metabolic or neurological issues in children.

DHA, an omega-3 long-chain polyunsaturated fatty acid, is important for maintaining normal placental function and aiding brain development during pregnancy. As concerns about contaminants, sustainability, and dietary preferences may limit reliance on marine DHA sources, demand for plant-based omega-3 fatty acids is growing.

Chia seeds are a plant-based source of alpha-linolenic acid (ALA), which the body converts to EPA and DHA. More research is needed to know how ALA from maternal sources supports fetal DHA during maternal obesity.

High-Fat Diet Pregnancy Study Design

Female Wistar rats were first fed a high-fat-high-sugar diet for six weeks to induce obesity before pregnancy. Once mated, the rats were separated into two groups depending on their diet for the duration of their pregnancy. One group did not change their diet throughout gestation, while the other group maintained the same diet plus whole chia seeds for extra ALA, a precursor to long-chain omega-3 fatty acids. The chia-enriched diet was substantially higher in ALA compared to the other group's diet. Animals were studied on gestational days 15 and 20, representing mid- and late-pregnancy stages linked to fetal brain development.

Maternal blood, adipose tissue, liver, placenta, and fetal brains were collected after euthanasia. The researchers measured maternal triglycerides, cholesterol, and leptin concentrations. Fatty acid composition in tissues was analyzed using gas chromatography and liquid chromatography coupled with mass spectrometry. In addition, gene expression analyses were conducted to determine the expression levels of enzymes involved in the metabolism of long-chain polyunsaturated fatty acids and in lipid transport to the fetus via the placenta. Western blotting was also used to assess FADS1 and FADS2 protein abundance in maternal liver tissue.

Statistical comparisons were conducted between dietary groups at each gestational stage to determine the metabolic effects of chia seed supplementation during obesity-associated pregnancy.

Maternal Omega-3 Metabolism Findings

Rats consuming the chia-supplemented diet ingested higher levels of ALA throughout pregnancy. Maternal body weight and organ weights remained unchanged, yet important metabolic improvements occurred. By late gestation, maternal blood triglyceride and cholesterol concentrations were significantly lower in the chia-fed group, suggesting improved lipid regulation despite continued exposure to a high-fat-high-sugar diet. Fetal body weight was modestly reduced at gestational day 20, while placental weight remained unchanged.

The most striking findings involved omega-3 fatty acid metabolism. Chia supplementation significantly elevated the levels of ALA, eicosapentaenoic acid, and DHA in maternal liver tissue collected during both mid and late gestation. At mid-gestation, liver DHA content was about 20% higher, and in late gestation, it was 40% higher. At the same time, several omega-6 fatty acids were reduced, although effects varied by tissue, gestational stage, and lipid species. These modifications suggested that the maternal liver actively handled and synthesized long-chain omega-3 fatty acids derived from plant ALA during gestation and fetal development.

Chia supplementation increased the omega-3 fatty acid content of maternal adipose tissue. Increased concentrations of DHA and eicosapentaenoic acid indicate that maternal tissue was storing beneficial fatty acids during pregnancy. Furthermore, the researchers observed greater incorporation of DHA into triglycerides and phosphatidylcholine molecules in blood plasma, two key carriers of fatty acid transport.

Placenta and Fetal Brain DHA Findings

Notable metabolic adaptations were evident in the placenta. Chia supplementation increased placental concentrations of ALA, eicosapentaenoic acid, and DHA during both gestational stages. The phospholipids became enriched in DHA-containing phosphatidylcholine and phosphatidylethanolamine species, which are important for membrane structure and lipid handling. Additionally, fatty acid transport genes were more prominently expressed, with emphasis on the major facilitator superfamily domain-containing protein 2A (MFSD2A), especially at the end of the gestation period. Overall, these placental changes suggested an increased capacity to handle and transfer long-chain omega-3 fatty acids, although transfer efficiency was not directly measured.

Importantly, fetal brain tissue also reflected these nutritional improvements. At mid-gestation, fetal brains from the chia-fed group contained higher levels of phospholipids enriched with ALA and DHA. However, these fetal brain lipid differences were not observed at gestational day 20. As DHA is a critical building block of neuronal membranes and brain development, these findings suggested that dietary chia seeds may enhance early brain lipid composition during critical developmental windows in this rat model.

Plant-Based DHA Pregnancy Implications

The findings demonstrated that adding chia seeds to a high-fat-high-sugar diet during pregnancy improved maternal omega-3 fatty acid metabolism and increased DHA availability to the placenta and fetal brain during mid-gestation. Maternal tissues also showed evidence of increased ALA synthesis and incorporation into beneficial long-chain omega-3 fatty acids, despite dietary stress associated with obesity.

The placenta's enhancement of lipid transport markers could improve the nutrition of the developing fetal brain during mid-gestation, a critical developmental window in the rat model. Therefore, these findings suggest that affordable plant-based foods, such as chia seeds, warrant further investigation as a potential strategy to improve maternal and fetal lipid profiles during obesity-associated pregnancy, although functional offspring outcomes and human relevance remain to be established.

Download your PDF copy by clicking here.

  • Dalix, G., Cloteau, C., Ouguerram, K., Castellano, B., Panheleux, A.-L., Grit, I., Winer, N., Boquien, C.-Y., & Ferchaud-Roucher, V. (2026). Chia seed enrichment in high-fat-high-sugar diet-induced obesity: A strategy to increase DHA levels in maternal tissues and in fetal placenta and brain during pregnancy. Prostaglandins, Leukotrienes and Essential Fatty Acids. 209. DOI: 10.1016/j.plefa.2026.102746 https://www.plefa.com/article/S0952-3278(26)00024-4/fulltext

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How can AI, in vitro systems, and omics technologies support reducing animal testing while maintaining scientific confidence?

There has been a regulatory drive to reduce animal testing for some time, including through frameworks such as the European Union’s REACH directive. More recently, we have seen this strengthened with roadmaps to phase out animal testing for chemical safety. In silico and in vitro methods are likely to be central to that transition. These tools can provide efficient, human-relevant, and multiscale evidence. One could imagine an approach similar to the carcinogenicity weight-of-evidence approach, in which in vitro and in silico data are gathered to justify reduced or no animal testing at specific points in the approval process. Regulatory acceptance remains challenging because standards vary around the world. For AI, there are also questions about model approval, model updates, benchmarking, and version control. It will be very interesting to see how regulators test and define these pathways.

Source: www.news-medical.net ↗
02What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
03What impact do you think the use of AI in drug discovery could ultimately have for patients?

One of the first ways in which this would be really felt by patients is through the repurposing of existing drugs for new diseases. Clearly, even though one could improve the process in a number of ways in terms of speeding up medicinal chemistry programs and potentially speeding up the amount of things such as toxicity trials etc., that is still going to take time. However, if we can take existing drugs, perhaps drugs which have gone off patent or are currently being marketed for another indication, and repurpose them in areas where there are high unmet medical needs, those drugs could go into that new indication in phase 2 in patients and you would know very quickly whether the drug worked or not. Then the route to market or the route to being able to make the drug more broadly available to patients would be much more rapid because you don't have to go through all those earlier stages of toxicity, testing, phase 1 testing, volunteers and so on.

Source: www.news-medical.net ↗
04What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
05How does vitamin D strengthen the immune system?

More specifically, the study showed that the female patient produced very few cathelicidins, which is a natural toxin found in the immune cells of the lungs needed to fight tuberculosis. In most people infected by tuberculosis, tuberculosis bacteria attack the immune cells of the lungs. The immune cells fight the bacteria by eating them. But the tuberculosis bacterium has developed various evasive mechanisms that reduce the immune cells’ ability to digest and thus to kill the Mtb. “You could say that the tuberculosis bacterium has developed a way to lull the immune cells to sleep. This enables the disease the hide inside the immune cells, making it invisible to other parts of the immune system,” Martin Kongsbak-Wismann explains. This is where vitamin D enters the picture. Because vitamin D is able to counteract the soporific effect of the tuberculosis bacteria by making the immune cells produce more of the cathelicidin toxin. “Cathelicidin is like a microscopic needle that is able to pierce the tuberculosis bacteria. And when it does, it weakens the bacteria’s soporific effect on the immune cells. This restores the immune cells’ ability to kill tuberculosis bacteria,” says Martin Kongsbak-Wismann and adds: “We were amazed by the effect of vitamin D. In immune cells from healthy control subjects, vitamin D improved the cells’ ability to fight Mtb, whereas in the female patient’s immune cells we saw no response to vitamin D. This shows that vitamin D is key to the immune system’s ability to fight Mtb and prevent tuberculosis.” Al-Jaberi, F.A.H., et al. (2022) Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Frontiers in Immunology. doi.org/10.3389/fimmu.2022.1038960.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →